GSK plc - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US37733W2044

SecurityGSK / GSK plc - Depositary Receipt (Common Stock)
InstitutionHantz Financial Services, Inc.
Latest Disclosed Ownership161,031 shares
Latest Disclosed Value $ 8,887
Hantz Financial Services, Inc. reports 6.67% increase in ownership of GSK / GSK plc - Depositary Receipt (Common Stock)

On May 1, 2026 - Hantz Financial Services, Inc. filed a 13F-HR form disclosing ownership of 161,031 shares of GSK plc - Depositary Receipt (Common Stock) (US:GSK) valued at $8,887,301 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 150,958 shares of GSK plc - Depositary Receipt (Common Stock). This represents a change in shares of 6.67% during the quarter. The current value of the position is $8,006,461 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F GSK USD 37733W204 161,031 10,073 6.67 9 14.29 0.1355
2026-02-09 2025-12-31 13F GSK USD 37733W204 150,958 18,904 14.32 7 40.00 0.1090
2025-11-05 2025-09-30 13F GSK USD 37733W204 132,054 22,393 20.42 6 25.00 0.0863
2025-08-04 2025-06-30 13F GSK USD 37733W204 109,661 7,515 7.36 4 33.33 0.0681
2025-05-12 2025-03-31 13F GSK USD 37733W204 102,146 14,730 16.85 4 50.00 0.0696
2025-01-23 2024-12-31 13F GSK USD 37733W204 87,416 7,858 9.88 3 -33.33 0.0515
2024-11-14 2024-09-30 13F GSK USD 37733W204 79,558 813 1.03 3 0.00 0.0577
2024-07-30 2024-06-30 13F GSK USD 37733W204 78,745 -2,746 -3.37 3 0.00 0.0583
2024-08-06 2024-03-31 13F/A GSK USD 37733W204 81,491 463 0.57 3 0.00 0.0681
2024-08-06 2023-12-31 13F/A GSK USD 37733W204 81,028 -927 -1.13 3 50.00 0.0655
2024-08-06 2023-09-30 13F/A GSK USD 37733W204 81,955 5,021 6.53 3 0.00 0.0754
2024-08-06 2023-06-30 13F/A GSK USD 37733W204 76,934 2,348 3.15 3 0.00 0.0687
2024-08-06 2023-03-31 13F/A GSK USD 37733W204 74,586 3,340 4.69 3 0.00 0.0724
2024-08-06 2022-12-31 13F/A GSK USD 37733W204 71,246 4,869 7.34 3 100.00 0.0756
2024-08-06 2022-09-30 13F/A GSK USD 37733W204 66,377 66,377 2 0.0674
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.